Wall Street Zen Downgrades EIKN (NASDAQ:EIKN) to Sell

EIKN (NASDAQ:EIKN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts have also recently weighed in on EIKN. Cantor Fitzgerald assumed coverage on EIKN in a report on Monday, March 2nd. They issued an “overweight” rating for the company. Morgan Stanley assumed coverage on EIKN in a report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price objective for the company. Bank of America initiated coverage on shares of EIKN in a report on Monday, March 2nd. They set a “buy” rating and a $34.00 target price on the stock. Finally, Wedbush assumed coverage on shares of EIKN in a research report on Thursday, February 26th. They set an “underperform” rating and a $7.00 target price on the stock. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Stock Performance

Shares of NASDAQ:EIKN opened at $14.38 on Friday. EIKN has a 52-week low of $13.28 and a 52-week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.